Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
CHIR-98014
Cat No.
CEI-0087
Description
CHIR-98014 can inhibit GSK-3alpha and GSK-3beta with Ki of 0.65 nM and 0.58 nM.
CAS No.
252935-94-7
Molecular Weight
486.31
Purity
>99%
Storage
2 years at -20 centigrade
Targets
GSK-3alpha, GSK-3beta
Molecular Formula
C20H17Cl2N9O2
Chemical Name
N2-(2-(4-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidin-2-ylamino)ethyl)-5-nitropyridine-2,6-diamine
Solubility
DSMO 4 mg/mL Water
In vitro
CHIR-98014 can inhibit GSK-3alpha and GSK-3beta with Ki of 0.65 nM and 0.58 nM. CHIR-98014 is a ATP binding competitive inhibitor and shows 500-fold to 10,000-fold selectivity for GSK-3 versus 20 other protein kinases. CHIR 98014 also showed similar potency against the highly homologous and isoforms of GSK-3, it is noteworthy that they strongly discriminated between GSK-3 and its closest homologs cdc2 and erk2. CHIR-98014 can activate glycogen synthase at approximately 100 nmol/l in cultured CHO cells transfected with the insulin receptor.
In vivo
In primary hepatocytes isolated from Sprague-Dawley rats, and at 500 nmol/l in isolated type 1 skeletal muscle of both lean Zucker and ZDF rats. CHIR-98014 can enhance insulin-stimulated glucose transport in type 1 skeletal muscle from the insulin-resistant ZDF rats but not from insulin-sensitive lean Zucker rats. Single oral doses of CHIR-98014 (30-48 mg/kg) rapidly lowered blood glucose levels and improved glucose disposal after oral or intravenous glucose challenges in ZDF rats and db/db mice, without causing hypoglycemia or markedly elevating insulin.
Download
Download Datasheet